Contepo (fosfomycin disodium)
Phosphonic Acid, Antibacterials Intravenous Vial (Ea)
Last reviewed · Source: First Databank (FDB) drug data
Overview
USES: This medication is used to treat bacterial infections. It works by stopping the growth of bacteria.
Generic name: fosfomycin disodium
Pronunciation: (FOS-foe-MYE-sin)
Drug class: Phosphonic Acid, Antibacterials
Therapeutic class: Anti-Infective Agents
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Contepo
Indications
No indications are available for this drug.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Contepo 6 Gram Vial | Maintenance | Infuse 6 gram over 1 hour(s) by intravenous route every 8 hours. |
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
Antibiotics/Fecal Microbiota
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Fecal microbiota is a suspension of live bacteria, which may be compromised by concurrent use of antibiotics.(1)
CLINICAL EFFECTS: Antibiotics may decrease the effectiveness of fecal microbiota.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Antibiotics should not be used concurrently with fecal microbiota. Antibacterial treatment should be completed for 24 to 72 hours before initiating treatment with fecal microbiota. Do not use antibiotics for up to 8 weeks after fecal microbiota.(1)
DISCUSSION: Antibiotics may compromise the effectiveness of fecal microbiota.
Antibiotics/Fecal Microbiota Spores
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Fecal microbiota spores is a suspension of live bacterial spores, which may be compromised by concurrent use of antibiotics.(1)
CLINICAL EFFECTS: Antibiotics may decrease the effectiveness of fecal microbiota spores.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Antibiotics should not be used concurrently with fecal microbiota spores. Antibacterial treatment should be completed for 2 to 4 days before initiating treatment with fecal microbiota spores.(1)
DISCUSSION: Antibiotics may compromise the effectiveness of fecal microbiota spores.
Antimicrobials/Live Typhoid Vaccine
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: The antimicrobial may be active against the organism in the live-vaccine. Antimicrobial therapy may prevent the vaccine organism from replicating enough to trigger an immune response.(1)
CLINICAL EFFECTS: Vaccination may be ineffective.
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Do not give oral typhoid vaccine until 72 hours after the last dose of antimicrobial. If possible, to optimize vaccine effectiveness, do not start antibacterial drugs for 72 hours after the last dose of oral typhoid vaccine. A longer interval should be considered for long-acting antimicrobials, such as azithromycin.(3)
DISCUSSION: Because antimicrobial therapy may prevent sufficient vaccine-organism replication to generate an immune response, the manufacturer of live-attenuated typhoid vaccine and the Centers for Disease Control (CDC) state that the vaccine should not be administered to patients receiving antimicrobial therapy.(1-3)
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
- Chronic kidney disease stage 3A (moderate) GFR 45-59 ml/min
- Chronic kidney disease stage 3B (moderate) GFR 30-44 ml/min
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Clostridioides difficile infection
- Congenital long QT syndrome
- Hypocalcemia
- Hypokalemia
- Prolonged QT interval
- Torsades de pointes
- Neutropenic disorder
Adverse reactions
There is no enhanced messaging for this drug.
Less Frequent
- Hypernatremia
- Hypokalemia
Rare or Very Rare
- Abnormal hepatic function tests
- Anaphylaxis
- Angioedema
- Aplastic anemia
- Bronchospastic pulmonary disease
- Clostridioides difficile infection
- Eosinophilia
- Thrombocytopenic disorder
Less Frequent
- Dysgeusia
- Erythema
- Injection site sequelae
- Skin rash
Rare or Very Rare
- Anorexia
- Diarrhea
- Dyspepsia
- Dyspnea
- Headache disorder
- Increased alanine transaminase
- Increased aspartate transaminase
- Nausea
- Petechiae
- Phlebitis after infusion
- Urticaria
- Visual changes
- Vomiting
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.